NovoCure director granted 11,610 shares
NovoCure Ltd director David Hung reported receiving equity awards on ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NovoCure Ltd director David Hung reported receiving equity awards on ordinary shares. He was granted 11,610 restricted stock units, bringing his direct holdings to 32,075 ordinary shares after the award. He also received options for 16,999 ordinary shares at an exercise price of $16.1500 per share. The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The options are scheduled to fully vest and become exercisable on the same timetable, and will expire on June 3, 2036 if not exercised.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,999 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 11,610 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
- F2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Key Figures
Key Terms
restricted stock units financial
Stock Option (Right to Buy) financial
exercise price financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.